Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

Rhea-AI Summary

Longeveron, a clinical stage biotech firm listed on NASDAQ as LGVN, will participate in the Virtual Life Sciences Investor Forum on June 20, 2024. The company focuses on developing cellular therapies for critical and aging-related conditions, such as hypoplastic left heart syndrome (HLHS) and Alzheimer’s disease. The event includes a fireside chat scheduled at 10:30 a.m. ET on June 20, 2024. The webcast can be accessed via the 'Events and Presentations' section of Longeveron's website, with a replay available for 90 days.

Positive

• Participation in the Virtual Life Sciences Investor Forum may increase visibility for Longeveron among investors.
• Focus on developing treatments for critical conditions like HLHS and Alzheimer's can attract interest from the medical community and investors.

Negative

• The press release lacks specific financial or clinical updates, which might disappoint shareholders seeking concrete progress reports.
• Absence of new data or breakthroughs in ongoing projects could be seen as a lack of significant progress.

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer’s disease, today announced that it will participate in the Virtual Life Sciences Investor Forum taking place June 20, 2024.

Details for the Company’s participation:

Fireside Chat Date: Fireside Chat Time:

Thursday, June 20, 2024 10:30 a.m. ET

The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 90 days following the conference.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. The Lomecel-B^TM HLHS program has received three distinct and important U.S. FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor Contact:

Derek Cole
Investor Relations Advisory Solutions 
derek.cole@iradvisory.com

FAQ

When is Longeveron's fireside chat at the Virtual Life Sciences Investor Forum?

Longeveron's fireside chat is scheduled for June 20, 2024, at 10:30 a.m. ET.

What conditions is Longeveron developing therapies for?

Longeveron is developing cellular therapies for hypoplastic left heart syndrome (HLHS) and Alzheimer's disease.

How can I access the webcast of Longeveron's presentation?

The webcast can be accessed through the 'Events and Presentations' section of Longeveron's website.

How long will the replay of Longeveron's presentation be available?

The replay will be available on Longeveron's website for 90 days following the conference.